Novo Nordisk's shares have plunged 36.3% over the past three months, driven by a weaker-than-expected 2026 outlook and intensified competition from Eli Lilly, which now dominates the weight-loss drug market. Despite a 10% revenue increase in 2025, the company is losing market share in key obesity and diabetes segments, while facing elevated price volatility. In response, Novo Nordisk is expanding its international market presence and pursuing strategic partnerships, including an initiative with OpenAI to enhance drug development.
“I had no interest in $NVO at $140 but I did at $55.”
“Biotech is one of the best way to play AI and $NVO is not gonna be the exception”
“$NVO: Same price as 2021, but revenue has doubled. All of these stocks offer asymmetric setups at current levels. Over the mid to long term, they are well positioned to capitalize on their strong fundamental growth and unlock significant upside potential.”
“Novo stock investors are disappointed that to start 2026, the share price is down over 3%. Investors were hoping that the approval of the weight loss pill and the start of sales of the weight loss treatment would be a boom to the company's sales and the share price would follow.”
“the management team is forecasting a not so stellar year in 2026, despite the approval of the weight loss pill, which again investors were hoping would be a big boom.”
“2025 delivered a year where Novo reported revenue increased by 10% and operating income only increased by 6%.”
“The company downgraded expectations multiple times in 2025, noting that the company was losing market share in the weight loss and diabetes markets.”
“Novo Nordis remains the number one overall GLP market leader with a 62% volume market share in international operations in the US.”
“Looking into 2026, they plan to further expand the obesity and diabetes markets into international segments.”
“Novo Nordisk remains the number one overall GLP market leader with a 62% volume market share in international operations in the US.”
“Novo is doing much better in international operations compared to the United States. Market share losses and realized lower prices are part of the reason why it's underperforming in the unit.”
“But Novo Nordisk underperformed last year and it's underperforming to begin 2025 2026. And one of the reasons is the pressure from the US administration.”
